Activating mutations of the epidermal growth factor receptor genes (EGFRm) are key oncogenic drivers in non-small cell lung cancer (NSCLC), with 85% of cases arising from in-frame deletions of exon 19 (del19) or exon 21 L858R point substitution1,2. This evidence concerns the gene EGFR and non-small cell lung carcinoma.